Chainshorts
Finance

RFK Jr.'s peptide policy could boost Hims & Hers as its GLP-1 business evolves

RFK Jr.'s peptide policy could boost Hims & Hers as its GLP-1 business evolves

Hims & Hers could expand its peptide business as FDA review in 2026 may boost revenue. The company’s potential growth hinges on regulatory approval for its GLP-1 products, which are gaining popularity for weight management and diabetes treatment. The evolving peptide market presents a significant opportunity for Hims to strengthen its position in biotech.

Share on XShare on Telegram

More in Finance

Finance

Australian Minister Says Fuel Reserves Up, More Shipments on Way

Australia’s Energy Minister Chris Bowen announced that fuel reserves have increased over the past week, with additional shipments expected. The rise in reserves aims to prevent shortages in the import-dependent country amid global supply concerns, supporting energy security and market stability.

Bloomberg MarketsApr 18Source ↗
Finance

Mortgage rates show signs of falling after Iran war peak

Mortgage rates are showing signs of decline following a peak during the Iran conflict, as major lenders reduce rates amid market optimism about a potential truce. The easing reflects market confidence and could influence housing affordability and borrowing costs in the coming months.

BBC BusinessApr 17Source ↗
All Finance